Should a PR firm or an interactive marketing agency be in charge of pharma social media campaigns?
Looming Challenges Cloud Implementation. This article reviews the strategic implications of the Sunshine Act and also presents highlights of the draft regulations rule released by the Centers for Medicare and Medicaid Services on December 15, 2011.
Welcome to Volume 10, Issue #5 (10 MARCH 2011) of Pharma Marketing News.
How much money the pharmaceutical industry spends on Internet marketing, direct-to-consumer advertising, and physician detailing are always topics of interest and 2010 was no exception. 2010 was, however, a turning point in bringing more attention to payments made to physicians for speaking, consulting, and research.
When asked what the # 1 concern pharmaceutical marketers have regarding using social media, the adverse event reporting (AER) boogey man is cited most often. The urge to avoid this boogey man at all costs may have more to do with CEO compensation that with fears of rank-an-file marketers.
Welcome to Volume 10, Issue #11 (21 JUNE 2011) of Pharma Marketing News.
Pharmaceutical marketers have jumped on the mobile application bandwagon as more and more companies roll out health-related applications for smartphones and touchpads such as Apple's iPhone and iPad. But will the FDA regulate certain smartphone apps as medical devices? This article discusses the regulatory and other issues associated with pharma developed or sponsored health apps.
A conversation with Monique Levy, VP Research at Manhattan Research, about the changing pharma eDetailing landscape. Ms. Levy discusses how the online pharma promotion landscape has changed, and which types of programs garner the largest audience as well as how the rep relationship is evolving and the role of new technologies such as tablets.
Welcome to Volume 10, Issue #10 (8 JUNE 2011) of Pharma Marketing News.
A study led by Mount Sinai School of Medicine researchers of 192 pharmaceutical advertisements (83 full unique advertisements) in biomedical journals found that only 18 percent (15) were compliant with Food and Drug Administration (FDA) guidelines, and over half failed to quantify serious risks including death.